

Thierry Chinet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1493226/publications.pdf>

Version: 2024-02-01

28
papers

946
citations

759233

12
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

1648
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Arteriovenous Malformations in Hereditary Hemorrhagic Telangiectasia. <i>Medicine (United States)</i> , 2015, 94, 10, e4211. doi:10.1093/med/94.10.e4211	1.0	83
2	Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. <i>OncolImmunology</i> , 2018, 7, e1452581.	4.6	115
3	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. <i>European Journal of Cancer</i> , 2017, 78, 16-23.	2.8	108
4	Discontinuing β -lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. <i>Lancet</i> , 2021, 397, 1195-1203.	13.7	82
5	Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. <i>OncolImmunology</i> , 2018, 7, e1424675.	4.6	66
6	Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. <i>Lung Cancer</i> , 2019, 137, 149-156.	2.0	63
7	Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. <i>Journal of Thoracic Oncology</i> , 2019, 7, 176.		62
8	Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. <i>PLoS ONE</i> , 2018, 13, e0195945.	2.5	46
9	Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis. <i>Journal of Clinical Immunology</i> , 2021, 41, 303-314.	3.8	41
10	Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?. <i>Cancers</i> , 2019, 11, 1269.	3.7	25
11	Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. <i>Journal of Thoracic Oncology</i> , 2020, 8, e000527.		24
12	Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e232-e234.	1.1	21
13	Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 1107.	3.7	16
14	Reliability of Contrast Echocardiography to Rule Out Pulmonary Arteriovenous Malformations and Avoid CT Irradiation in Pediatric Patients with Hereditary Hemorrhagic Telangiectasia. <i>Echocardiography</i> , 2015, 32, 42-48.	0.9	15
15	Occurrence of pulmonary embolism related to COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 69-75.	2.1	14
16	Acute exacerbation of COPD during pulmonary rehabilitation: outcomes and risk prediction. <i>International Journal of COPD</i> , 2018, Volume 13, 1767-1774.	2.3	12
17	Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia. <i>JAMA Network Open</i> , 2021, 4, e2129566.	5.9	10
18	Feasibility of spirometry in primary care to screen for COPD: a pilot study. <i>International Journal of COPD</i> , 2016, 11, 335.	2.3	8

#	ARTICLE	IF	CITATIONS
19	Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case. BMC Cancer, 2015, 15, 732.	2.6	7
20	Effect of pulmonary arteriovenous malformations on the mechanical properties of the lungs. BMC Pulmonary Medicine, 2017, 17, 64.	2.0	6
21	Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 97.	3.7	6
22	Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. Oncotarget, 2017, 8, 109818-109835.	1.8	5
23	Higher prevalence of splenic artery aneurysms in hereditary hemorrhagic telangiectasia: Vascular implications and risk factors. PLoS ONE, 2020, 15, e0226681.	2.5	4
24	How to follow-up patients with hereditary haemorrhagic telangiectasia and suspected pulmonary arteriovenous malformations. European Respiratory Journal, 2016, 47, 1618-1621.	6.7	3
25	Severe, chronic cough caused by pulmonary arteriovenous malformations in a patient with hereditary haemorrhagic telangiectasia: case report. BMC Pulmonary Medicine, 2015, 15, 28.	2.0	1
26	Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, XD01-XD03.	0.8	1
27	Pulmonary gas exchange in hereditary hemorrhagic telangiectasia patients with liver arteriovenous malformations. Respiratory Research, 2019, 20, 137.	3.6	1
28	Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients. PLoS ONE, 2019, 14, e0219080.	2.5	1